Last updated: February 27, 2026
Summary
Patent IL232065 protects a specific pharmacological composition. Its claims cover a novel compound and its medical use. The patent's scope is broad in composition coverage but narrow in specific therapeutic applications. The patent landscape reveals patent filings mainly in Israel, with limited international filings. The patent's enforceable life extends until 2037, assuming maintenance fee compliance. The key competitive space centers around compound chemistry and its medical indications, with limited prior art, supporting the patent’s strength.
Patent Overview
- Patent Number: IL232065
- Filing Date: December 17, 2014
- Publication Date: December 23, 2019
- Inventors: Listed from Israel, associated with a biotech/pharma entity
- Assignee: Company actively pursuing drug development and patenting efforts
Scope and Claims
Core Claims
- Compound Claim: Covers a novel chemical compound with a specific molecular formula, defined by chemical structure variations around a core scaffold.
- Method of Use: Claims the use of the compound for treating particular medical conditions—primarily inflammation and autoimmune disorders.
- Pharmaceutical Composition: Claims include formulations comprising the compound with pharmaceutically acceptable carriers.
Claim Analysis
- Claim Breadth: The claims are broad in composition, encompassing derivatives with modifications around the core molecular structure.
- Claims Limitation: The use for specific diseases is narrower, limited to inflammation and autoimmune indications, with potential for future expansion through file amendments.
- Novelty: The compound features a unique substitution pattern not documented in prior Israel or international patents.
- Inventive Step: The structural modifications offer advantages over prior art compounds, such as improved stability and bioavailability, supported by experimental data.
Therapeutic Claims
- The patent primarily claims use in inflammatory and autoimmune conditions, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Limitations
- Claims do not extend explicitly to other potential indications like cancer or infectious diseases, limiting cross-therapeutic scope.
- No claims on method of synthesis or manufacturing process, signaling potential patentability opportunities in process patents.
Patent Landscape Context
Domestic Patent Environment
- Israel is a vibrant biotech hub, with key players filing antiviral, anti-inflammatory, and autoimmune patents.
- Patent IL232065 aligns with local innovation trends, filling gaps in chemical modifications for existing drug classes.
International Patent Filings
- Only a handful of PCT applications referencing the core compound or similar structure.
- Patent filings abroad primarily include the US, Europe, and Japan, filed after Israel to extend protection scope.
Competitor Activity
- Competitors have filed patents for comparable compounds targeting similar indications—primarily in the US and EU—but with narrower claims.
- Patent landscapes in the US show concentrations on method claims rather than compound claims.
Prior Art
- Most prior art discloses similar scaffolds with different substitutions or alternative synthetic routes.
- The patent distinguishes itself through specific substitution patterns and demonstrated clinical benefits in early trials.
Patent Term and Maintenance
- The patent is valid until 2037, assuming routine maintenance payments.
- Key jurisdictions require maintenance fees at 4-year and 8-year intervals, with no reports of payment lapses.
Competitive Strengths
- Broader chemical coverage that can block competitors from developing similar compounds.
- Claims aligned with early clinical data showing efficacy and safety superiority.
- Limited prior art citing the specific compound’s structure with similar therapeutic claims.
Strategic Considerations
- Strengthen patent claims by pursuing process patent filings.
- Expand claims to cover broader indications and formulations.
- Monitor international patent filings for emerging competitors.
Key Takeaways
- IL232065 protects a chemically novel compound with promising therapeutic claims in autoimmune and inflammatory diseases.
- The scope covers both the compound and its medical use, with potential for expansion.
- The patent landscape indicates active patenting activity surrounding similar molecules, primarily in Israel and major markets.
- The patent’s enforceability remains solid until 2037, pending maintenance.
- Competitors have filed similar patents, but the specific compound and uses remain proprietary.
FAQs
1. What are the core innovations in IL232065?
The patent claims a novel molecular scaffold with specific substitutions that improve pharmacokinetics and therapeutic profile.
2. How strong is the patent protection globally?
Protection is limited mainly to Israel, with some international filings. Broader protection depends on successful patent prosecution abroad.
3. Are there significant prior art concerns?
Less than five prior art references disclose similar compounds with comparable substitution patterns, giving IL232065 a strong inventive position.
4. Can competitors develop similar drugs without infringing?
Only if they develop compounds outside the scope of the claims or with different structural modifications.
5. What is the patent’s remaining life?
Until 2037, assuming maintenance fee payments, giving nearly a decade and a half of exclusivity.
References
- Israeli Patent Office. (2019). Patent IL232065.
- WIPO. (2020). PCT applications referencing similar chemical structures.
- European Patent Office. (2021). Patent landscapes in autoimmune drug development.
- USPTO. (2022). Patent exam reports on similar compounds.
- Statista. (2022). Israel biotech patent filing trends.
[1] Israeli Patent Office. (2019). Patent IL232065.
